

BIO-TECHNE Corp  
 Form 4  
 April 04, 2016

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**Hippel James**

(Last) (First) (Middle)  
 614 MCKINLEY PLACE N.E.  
 (Street)

MINNEAPOLIS, MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**BIO-TECHNE Corp [TECH]**

3. Date of Earliest Transaction (Month/Day/Year)  
 03/31/2016

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 \_\_\_\_ Officer (give title below) \_\_\_\_\_ Other (specify below)  
 Chief Financial Officer

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2016		M		1,666	A	11
Common Stock	03/31/2016		F		556	D	\$ 94.52
					6,100	(2)	
					5,544		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

Edgar Filing: BIO-TECHNE Corp - Form 4

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Restricted Stock Units	(1)	03/31/2016		M	1,666	(3) (3)	Common Stock	1,666
Restricted Stock Units	(1)					(4) (4)	Common Stock	3,000
Stock Options (Right to Buy)	\$ 108.49					(4) 08/07/2022	Common Stock	12,500
Stock Options (Right to buy)	\$ 108.49					(5) 08/07/2022	Common Stock	25,000
Stock Options (Right to Buy)	\$ 94.35					(6) 08/12/2021	Common Stock	35,000
Stock Options (Right to Buy)	\$ 86.25					(7) 04/01/2021	Common Stock	10,000
Stock Options (Right to buy)	\$ 86.25					(8) 04/01/2021	Common Stock	25,000

## Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Hippel James  
614 MCKINLEY PLACE N.E.  
MINNEAPOLIS, MN 55413

Chief Financial Officer

## Signatures

/s/ Elizabeth M. Dunshee as Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed.

04/04/2016

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
- (2) Includes 1,667 shares of restricted stock units that vest on 3/31/2017 (previously reported on Table II).
- (3) On April 1, 2014, the reporting person was granted 5,000 restricted stock units, vesting in three equal annual installments beginning on March 31,2015.
- (4) Vests in full or in part if certain performance goals are achieved during each of the 2016, 2017 and 2018 fiscal years.
- (5) 6,250 shares vest on each of 8/7/2016, 8/7/2017, 8/7/2018 and 8/7/2019.
- (6) 8,750 shares vest on each of 8/12/2015, 8/12/2016, 8/12/2017 and 8/12/2018.
- (7) Vests in full or in part if certain performance goals are achieved.
- (8) 6,250 shares vest on each of 4/1/2015, 4/1/2016, 4/1/2017 and 4/1/2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.